![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Pipeline
Pipeline
May 20, 2019
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Tolero Pharmaceuticals, Inc. | TP-3654 | advanced solid tumors | Phase I trial initiated |
Tempest Therapeutics Inc. | TPST-1120 | advanced solid tumor malignancies | Phase I/Ib trial initiated enrolling subjects with advanced solid tumors |
ORIC Pharmaceuticals | ORIC-101 in combination with nab-paclitaxel | advanced solid tumors | Phase Ib trial initiated |
InflaRx | IFX-1 | ANCA-associated vasculitis (AAV) | Phase II trial initiated enrolling 80 subjects at 60 sites across 12 European countries and Russia |
Rigel Pharmaceuticals, Inc. | fostamatinib disodium hexahydrate (fostamatinib) | warm antibody autoimmune hemolytic anemia (AIHA) | Phase III trial initiated enrolling 80 subjects in the U.S. |
ReGenTree, LLC | RGN-259 eye drops | dry eye syndrome | Phase III trial initiated enrolling 700 subject at 15 sites in the U.S. |
Haemonetics Corporation | 6s Hemostasis Analyzer System | adult trauma | 510(k) clearance granted by the FDA |
Transgene | TG4050 | ovarian cancer | IND approval granted by the FDA |
Merz Americas | XEOMIN (incobotulinumtoxinA) | blepharospasm (involuntary blinking) | sBLA approval granted by the FDA |
AliveCor | KardiaMobile 6L six-lead personal ECG device | cardiovascular disease | Clearance granted by the FDA |
Genentech and AbbVie | Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) | previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | Approval granted by the FDA |
EMD Serono and Pfizer, Inc. | BAVENCIO (avelumab) in combination with INLYTA (axitinib) | advanced renal cell carcinoma (RCC) | Approval granted by the FDA |
Eli Lilly and Company | CYRAMZA (ramucirumab injection, 10 mg/mL solution) | hepatocellular carcinoma (HCC) | Approval granted by the FDA |
Regeneron Pharmaceuticals, Inc. | EYLEA (aflibercept) Injection | diabetic retinopathy (DR) | Approval granted by the FDA |
Upcoming Events
-
21Oct